Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   85 Trials   85 Trials   3645 News 


«12...2930313233343536373839...4546»
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Burkitt Lymphoma — Subtypes, Pathogenesis, and Treatment Strategies () -  Sep 14, 2020 - Abstract #SOHO2020SOHO_310;    
    Regimens such as RCHOP provide far inferior survival...Historically, the addition of high-dose methotrexate and cytarabine have improved outcomes...Thus, recent breakthroughs such as CAR-T are relegated to anecdotes in BL. The bispecific antibody, blinatumomab, is similarly underexplored.13 BL remains a highly curable disease but with a dismal outcome for the roughly 15% of patients for whom it is fatal.
  • ||||||||||  Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Blincyto (blinatumomab) / Astellas, Amgen, dasatinib / Generic mfg.
    [VIRTUAL] Intensive Versus Non-Intensive Approach to Adults with Ph+ ALL: An Intensive Approach Is Still Standard of Care () -  Sep 14, 2020 - Abstract #SOHO2020SOHO_303;    
    As we evaluate these new, emerging regimens, they should be compared to the 5-year OS of 74% that has been achieved with the hyper-CVAD plus ponatinib regimen (a regimen that can safely spare most patients from HSCT in first remission and achieves a 5-year OS of 83% in non-transplanted patients). Enrollment of patients onto innovative clinical trials remain critical to answer these important questions and to provide evidence-based support for the use of lower-intensity regimens in these patients.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal, CAR T-Cell Therapy:  CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. (Pubmed Central) -  Sep 9, 2020   
    However, prior therapy with the CD19-directed, bispecific T-cell engager blinatumomab was associated with a significantly higher rate of failure to achieve MRD- remission or subsequent loss of remission with antigen escape. Finally, immunophenotypic heterogeneity and lineage plasticity were independent of underlying clonotype and cytogenetic abnormalities.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo
    [VIRTUAL] My T Cell: A smartphone app for the management of CAR T and BiTE-associated toxicities (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_2209;    
    “My T cell” has the potential to become a highly usable smartphone app supporting the application of T-cell recruiting immunotherapies and the education of health care professionals. Thus, we aim to increase patient safety and accelerate the broader and safer application of CARs and BiTEs.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo
    [VIRTUAL] My T Cell: A smartphone app for the management of CAR T and BiTE-associated toxicities (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1495;    
    “My T cell” has the potential to become a highly usable smartphone app supporting the application of T-cell recruiting immunotherapies and the education of health care professionals. Thus, we aim to increase patient safety and accelerate the broader and safer application of CARs and BiTEs.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    [VIRTUAL] First Line Use of Immunotherapies - What to Consider (San Francisco) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_1386;    
    T-cell based immunotherapies, including the bispecific T cell engager blinatumomab and CD19-specific CAR T cells, are major innovations in the treatment of B cell malignancies...Due to the high complexity and cost of CAR T cell therapy as well as their acute toxicities and potential late effects, e.g. sustained B cell depletion and hypogammaglobulinemia, superiority over current therapies will have to be clearly demonstrated. Immune therapy trials must be accompanied by well-designed immune monitoring programs that provide key insights into the mechanisms determining response and pave the way to the effective future use of T cell-based therapies in ALL.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Yescarta (axicabtagene ciloleucel) / Gilead, Daiichi Sankyo
    [VIRTUAL] My T Cell: A smartphone app for the management of CAR T and BiTE-associated toxicities (Abstract video presentations) -  Sep 3, 2020 - Abstract #DGHO2020DGHO_701;    
    “My T cell” has the potential to become a highly usable smartphone app supporting the application of T-cell recruiting immunotherapies and the education of health care professionals. Thus, we aim to increase patient safety and accelerate the broader and safer application of CARs and BiTEs.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Journal:  Recent advances in the treatment of acute lymphoblastic leukemia. (Pubmed Central) -  Aug 30, 2020   
    Ongoing efforts exist to optimize therapeutic options in both the relapsed/refractory as well as the frontline settings. In the era of precision medicine, the future lies in using less cytotoxic and more targeted agents.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal:  Bone Marrow Necrosis in a Patient Following Blinatumomab Therapy. (Pubmed Central) -  Aug 19, 2020   
    Here, we report an adolescent boy with relapse/resistant acute lymphoblastic leukemia developing BMN following blinatumomab therapy. To our knowledge, this is the first case report on BMN following blinatumomab treatment.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Clinical, Journal:  Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. (Pubmed Central) -  Aug 18, 2020   
    P1
    These results indicate that 60 µg/m per day seems to represent the targeted dose level of blinatumomab required for durable remission in R/R B-NHL. Here, we provide the first clinical evidence that blinatumomab lacks long-term toxicity and has the potential to induce sustained remissions in patients with R/R B-NHL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment change, Trial completion date, Trial primary completion date, Minimal residual disease:  Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Aug 12, 2020   
    P2,  N=80, Recruiting, 
    Jae Park summarized clinical data from key trials of novel immunotherapies in ALL and reviewed evidence-based treatment approaches for adults with relapsed/refractory B-cell ALL. N=60 --> 80 | Trial completion date: Jan 2021 --> Jan 2023 | Trial primary completion date: Jul 2020 --> Jul 2021
  • ||||||||||  Nailike (olverembatinib) / Ascentage Pharma, Takeda
    Trial completion date, Trial primary completion date:  HQP1351CU101: Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL (clinicaltrials.gov) -  Aug 11, 2020   
    P1,  N=30, Recruiting, 
    N=60 --> 80 | Trial completion date: Jan 2021 --> Jan 2023 | Trial primary completion date: Jul 2020 --> Jul 2021 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial initiation date, Pre-transplantation:  Pediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study (clinicaltrials.gov) -  Aug 10, 2020   
    P2,  N=110, Not yet recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2020 --> Dec 2021 Initiation date: May 2020 --> Sep 2020
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. (Pubmed Central) -  Aug 8, 2020   
    In addition, there have been recent developments in minimal/measurable residual disease (MRD) testing and blinatumomab use in the context of MRD-positive disease after therapy. These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Trial completion date, Trial primary completion date:  EWALL-BOLD: Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab (clinicaltrials.gov) -  Aug 8, 2020   
    P2,  N=50, Recruiting, 
    These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines for ALL regarding upfront therapy in older adults and MRD monitoring/testing in response to ALL treatment. Trial completion date: Mar 2021 --> Jan 2023 | Trial primary completion date: Mar 2020 --> Sep 2022
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  Advances in the Treatment of Adult Acute Lymphoblastic Leukemia. (Pubmed Central) -  Aug 7, 2020   
    In an effort to improve outcomes while minimizing toxicities, novel targeted therapies have been developed: monoclonal antibodies against CD19, CD20, and CD22; tyrosine kinase inhibitors; chimeric antigen receptor T-cell therapies; and BH3 mimetics. Here, we discuss advancements in the treatment of ALL and their places in the armamentarium for adult patients.
  • ||||||||||  Kymriah (tisagenlecleucel-T) / Novartis, Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Review, Journal:  Targeted therapy paves the way for the cure of acute lymphoblastic leukaemia. (Pubmed Central) -  Aug 6, 2020   
    This has led to tremendous improvement in long-term survival, of more than 50% in patients with precursor B-ALL [50-70% in patients with Philadelphia chromosome (Ph)-positive ALL)], 50-60% in T-ALL and 80% in mature B-ALL. Research is ongoing to optimize the benefit of targeted therapeutics with the goal of decreasing the use of cytotoxic therapies.
  • ||||||||||  Journal:  Azole antifungals and new targeted therapies for hematological malignancy. (Pubmed Central) -  Aug 4, 2020   
    With the emergence of novel agents, clinical judgment must be used to assess the risk of developing an IFD. Care must also be taken when administering azoles with drug--drug interactions, often requiring dose adjustment of the cancer therapies.
  • ||||||||||  Review, Journal:  Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies. (Pubmed Central) -  Jul 30, 2020   
    As additional tools become available for lymphoma treatment, formulation of safe, rational combination strategies to combine them with standard therapy will be of paramount importance. A successful approach to the treatment of lymphoma may require both an optimized anti-tumor immune response as well as effective depletion of malignant lymphoid cells.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
    Clinical, Review, Journal:  Current treatment strategies for Philadelphia chromosome-positive adult acute lymphoblastic leukemia. (Pubmed Central) -  Jul 30, 2020   
    Potent TKIs and monoclonal antibodies, such as blinatumomab and inotuzumab, have improved patient outcomes in relapse and refractory cases of ALL. The introduction of effective agents, such as potent TKIs and monoclonal antibodies, may improve the possibility of remission in Ph-positive ALL patients and hopefully cure this disease.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / BMS, Imbruvica (ibrutinib) / AbbVie, J&J
    Trial primary completion date:  Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation (clinicaltrials.gov) -  Jul 27, 2020   
    P2,  N=10, Active, not recruiting, 
    No abstract available Trial primary completion date: Jun 2020 --> Jun 2021